THE increasing enthusiasm for treating thromboembolic diseases with prothrombin-reducing drugs for long periods in ambulatory patients has emphasized the lack of clear definition of the therapeutic ...
Thirteen patients with liver disease and an abnormal prothrombin time refractory to vitamin K therapy were studied (Tables 1 and 2). None of the patients were actively bleeding, and none had received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results